08/04/2026
Closing the gap in brain cancer research together
We are excited to announce a strategic collaboration between Dynamic42 and Experimental Pharmacology & Oncology Berlin-Buch GmbH to tackle one of the biggest challenges in brain cancer research: the lack of human-relevant preclinical models.
By combining Dynamic42’s organ-on-chip technology with EPO’s translational oncology expertise and patient-derived tumor models, we aim to improve the translational relevance of preclinical data—starting with glioblastoma and the blood–brain barrier (BBB).
Our joint goal:
/ Generate more human-relevant insights early in drug development by combining advanced in vitro and in vivo approaches
/ Reduce late-stage failure risks
/ Support biology-driven research and the 3Rs principles
👉 Learn more in this press release: https://zurl.co/4yiOp
We are proud to introduce our results from this joint project at in San Diego from April 19-22.
Where to meet us:
📌 Evening Reception hosted by EPO & Dynamic42: April 19, starting from 6 p.m. PDT at The East Village Brewing Company
📌 Poster #3401, April 20, 2-5 p.m. PDT (Session In Vitro Models 1: 2D and 3D, Section 28, Board 6)
Modelling the multicellular blood-brain barrier with a PDX-derived glioblastoma microenvironment: comparing human and mouse biochip systems for tumor heterogeneity and drug response (Amélie Paillereau, in collaboration with EPO)
“Not affiliated with or endorsed by AACR.”